Published in Atherosclerosis on December 13, 2005
C-reactive protein and venous thromboembolism. A prospective investigation in the ARIC cohort. Thromb Haemost (2009) 1.11
An evaluation of candidate genes of inflammation and thrombosis in relation to the risk of venous thromboembolism: The Women's Genome Health Study. Circ Cardiovasc Genet (2009) 0.89
Inflammation markers and incident venous thromboembolism: the REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort. J Thromb Haemost (2014) 0.86
High-sensitivity C-reactive protein is not a risk factor for venous thromboembolism: the Tromso study. Haematologica (2011) 0.81
Yeast vectors for the controlled expression of heterologous proteins in different genetic backgrounds. Gene (1995) 13.86
Regulatable promoters of Saccharomyces cerevisiae: comparison of transcriptional activity and their use for heterologous expression. Nucleic Acids Res (1994) 10.72
Mefloquine compared with other malaria chemoprophylactic regimens in tourists visiting east Africa. Lancet (1993) 5.99
Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet (1992) 5.59
CPF1, a yeast protein which functions in centromeres and promoters. EMBO J (1990) 3.65
Wilson's disease in patients presenting with liver disease: a diagnostic challenge. Gastroenterology (1997) 3.52
Increased fetal loss in women with heritable thrombophilia. Lancet (1996) 3.34
High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med (2000) 2.86
Genetic fingerprinting in mouthwashes of patients after allogeneic bone marrow transplantation. Bone Marrow Transplant (1999) 2.53
Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg (2010) 2.52
Heme oxygenase-1 gene promoter microsatellite polymorphism is associated with restenosis after percutaneous transluminal angioplasty. J Endovasc Ther (2001) 2.51
Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol (2008) 2.24
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
Alternative splicing of human cyclin E. J Cell Sci (1994) 2.20
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost (2005) 2.13
Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb Haemost (1994) 2.09
Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. Gut (2000) 2.08
Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost (1996) 2.07
Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH. J Thromb Haemost (2014) 2.04
Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res (2001) 1.98
Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol (2008) 1.88
Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill? Crit Care Med (2003) 1.87
Association of an ABCB1 gene haplotype with pharmacoresistance in temporal lobe epilepsy. Neurology (2004) 1.87
EID1, an F-box protein involved in phytochrome A-specific light signaling. Genes Dev (2001) 1.85
An autonomous N-terminal transactivation domain in Fos protein plays a crucial role in transformation. EMBO J (1994) 1.83
Alternative end-joining in follicular lymphomas' t(14;18) translocation. Leukemia (2002) 1.71
Follicular lymphomas' BCL-2/IgH junctions contain templated nucleotide insertions: novel insights into the mechanism of t(14;18) translocation. Blood (2000) 1.70
Gender differences in symptom presentation associated with coronary heart disease. Am J Cardiol (1999) 1.69
Coagulation factor XII (FXII) activity, activated FXII, distribution of FXII C46T gene polymorphism and coronary risk. J Thromb Haemost (2007) 1.68
Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol (2001) 1.68
Is elevated mean platelet volume associated with a worse outcome in patients with acute ischemic cerebrovascular events? Stroke (2004) 1.66
Requirement of residual thymus to restore normal T-cell subsets after human allogeneic bone marrow transplantation. Transplantation (2000) 1.55
The use of dexamethasone in women with preterm premature rupture of membranes--a multicentre, double-blind, placebo-controlled, randomised trial. Dexiprom Study Group. S Afr Med J (1999) 1.53
Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood (2001) 1.46
Use of conditional promoters for expression of heterologous proteins in Saccharomyces cerevisiae. Methods Enzymol (1997) 1.45
Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost (2004) 1.44
Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol (2003) 1.44
Incidence of pseudoaneurysm after diagnostic and therapeutic angiography. Radiology (1995) 1.43
Evidence of carotid atherosclerosis in orthopantomograms and the risk for future cardiovascular events. Vasa (2010) 1.43
The presence of IgG antibodies against beta2-glycoprotein I predicts the risk of thrombosis in patients with the lupus anticoagulant. J Thromb Haemost (2005) 1.43
The risk of recurrent venous thromboembolism among patients with high factor IX levels. J Thromb Haemost (2003) 1.42
Transient lupus anticoagulants in children: stepwise disappearance of diagnostic features. Thromb Haemost (2000) 1.39
Influence of systemic inflammation on efficiency of antiplatelet therapy in PAOD patients. Ann Hematol (2003) 1.39
Femoropopliteal artery: initial and 6-month results of color duplex US-guided percutaneous transluminal angioplasty. Radiology (1996) 1.37
The MELANIE project: from a biopsy to automatic protein map interpretation by computer. Electrophoresis (1991) 1.35
Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost (2012) 1.29
Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg (1991) 1.29
The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost (2009) 1.28
Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene. Neurology (2005) 1.28
High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). J Thromb Haemost (2009) 1.28
Barriers to completion of tuberculosis treatment among prisoners and former prisoners in St. Petersburg, Russia. Int J Tuberc Lung Dis (2005) 1.26
High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia (2005) 1.24
Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem (1995) 1.22
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost (2013) 1.21
When should prophylactic treatment in patients with haemophilia A and B start?--The German experience. Haemophilia (1998) 1.16
Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol (1998) 1.16
Multiplex PCR for rapid detection of T-cell receptor-gamma chain gene rearrangements in patients with lymphoproliferative diseases. Br J Haematol (1996) 1.15
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia (2009) 1.15
Inflammatory response and myocardial injury following coronary artery bypass grafting with or without cardiopulmonary bypass. Eur J Cardiothorac Surg (2000) 1.13
Platelets in hyperthyroidism: studies on platelet counts, mean platelet volume, 111-indium-labeled platelet kinetics, and platelet-associated immunoglobulins G and M. J Clin Endocrinol Metab (1990) 1.13
Cyclin ET, a new splice variant of human cyclin E with a unique expression pattern during cell cycle progression and differentiation. Nucleic Acids Res (1997) 1.13
High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol (2009) 1.13
[Safety of high risk in vitro diagnostic medical devices : international and national measures]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz (2009) 1.12
The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. J Thromb Haemost (2005) 1.12
Antiplatelet treatment prolongs survival after carotid bifurcation endarterectomy. Analysis of the clinical series followed by a controlled trial. Ann Surg (1990) 1.12
Clinical in vitro endothelialization of femoropopliteal bypass grafts: an actuarial follow-up over three years. J Vasc Surg (1994) 1.11
Evidence of a U-shaped association between factor XII activity and overall survival. J Thromb Haemost (2007) 1.10
Identification of a novel mitogen-inducible gene (mig-6): regulation during G1 progression and differentiation. Exp Cell Res (1995) 1.09
Sinus node dysfunction after orthotopic cardiac transplantation: postoperative incidence and long-term implications. Pacing Clin Electrophysiol (1992) 1.08
Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood (1995) 1.07
Clinical significance of lupus anticoagulants in children. J Pediatr (1999) 1.07
Functional asplenia after bone marrow transplantation. A late complication related to extensive chronic graft-versus-host disease. Ann Intern Med (1988) 1.06
The prevalence of factor XII deficiency in 103 orally anticoagulated outpatients suffering from recurrent venous and/or arterial thromboembolism. Thromb Haemost (1992) 1.06
Immunoreactivity of B-cell markers (CD79a, L26) in rare cases of extranodal cytotoxic peripheral T- (NK/T-) cell lymphomas. Mod Pathol (2000) 1.06
CD5 expression in a lymphoma of the mucosa-associated lymphoid tissue (MALT)-type as a marker for early dissemination and aggressive clinical behaviour. Leuk Lymphoma (2001) 1.05
Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost (2011) 1.05
PTA versus carbofilm-coated stents in infrapopliteal arteries: pilot study. Cardiovasc Intervent Radiol (2006) 1.05
Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden. Thromb Haemost (1999) 1.05
Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients. Antimicrob Agents Chemother (1999) 1.04
Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost (1998) 1.03
Thrombin generation in morbid obesity: significant reduction after weight loss. J Thromb Haemost (2010) 1.02
Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia (2002) 1.01
Risk stratification for subclavian artery angioplasty: is there an increased rate of restenosis after stent implantation? J Endovasc Ther (2001) 1.01
Computerized classification of two-dimensional gel electrophoretograms by correspondence analysis and ascendant hierarchical clustering. Appl Theor Electrophor (1988) 1.01
Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost (2001) 1.01
A common C-->T polymorphism at nt 46 in the promoter region of coagulation factor XII is associated with decreased factor XII activity. Thromb Res (2001) 1.00